Published on 7 Sep 2023 on Simply Wall St. via Yahoo Finance
With its stock down 10% over the past three months, it is easy to disregard Royalty Pharma (NASDAQ:RPRX). It is possible that the markets have ignored the company's differing financials and decided to lean-in to the negative sentiment. Fundamentals usually dictate market outcomes so it makes sense to study the company's financials. Particularly, we will be paying attention to Royalty Pharma's ROE today.
Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.
View our latest analysis for Royalty Pharma